Acquisition Completed

Ligand Pharmaceuticals acquisition of XOMA Royalty

US$739m equity value

Announced 27 Apr 2026 · NASDAQ: XOMA · US$39.00 cash per share

Advisers

XOMA Royalty

Target

Legal adviser
Fairness opinion

Ligand Pharmaceuticals Incorporated

Acquirer

Financial adviser
Legal adviser
Communications
Target
XOMA Royalty
Acquirer
Ligand Pharmaceuticals Incorporated
Target based in
United States
Buyer based in
United States
Completed
14 Jul 2026
Sector
Specialty finance and leasing
Tags
Specialty finance and leasing, Biotech, Life Sciences

In the league tables

Similar deals

All specialty finance and leasing deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.